[The use of BCG for the prevention of recurrence of superficial bladder tumors: 10 year's experience].
The aim of this study was evaluate the usefulness of intravescical administration of Bacillus of Calmette Guerin (BCG) in patients with superficial bladder cancer. The BCG, an immunostimulating agent, has been introduced in routine clinical use; according to the international literature, it is reported to offer better result than the above-mentioned drugs. A retrospective analysis was made of 210 patients who had undergone a complete TUR for superficial bladder tumor. The irritative symptoms and systemic effects are acceptables considering the benefit of the BCG. The results are of great interest and encourage us to continue this study to confirm therapeutic strength.
Sampalmieri
G
G
Servizio di Urologia, Ospedale S. Spirito in Sassia, Roma.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009163:Mycobacterium bovis; D012008:Recurrence; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*